This Article Full Text Full Text (PDF) All Versions of this Article: 149/6/2866    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Gao, L. Articles by Ni, X. PubMed PubMed Citation Articles by Gao, L. Articles by Ni, X.

Differential Regulation of Prostaglandin Production Mediated by Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 in Cultured Human Placental Trophoblasts

Department of Physiology (L.G., C.L., C.X., B.C., X.N.) and Changhai Hospital (Y.T.), Second Military Medical University, Shanghai 200433, People’s Republic of China; and Department of Physiology (C.L.), Harbin Medical University, Harbin 150086, People’s Republic of China

Address all correspondence and requests for reprints to: Dr. Xin Ni, Department of Physiology, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People’s Republic of China. E-mail: nxljq2003{at}yahoo.com.cn.

Prostaglandin (PG) production by intrauterine tissues plays a key part in the control of pregnancy and parturition. The present study was to investigate the role of placenta-derived CRH and CRH-related peptides in the regulation of PG synthesis and metabolism. We found that placental trophoblasts expressed both CRH-R1 and CRH-R2. Treatment of cultured placental cells with either a CRH or urocortin I (UCNI) antibody resulted in a significant decrease in PGE₂ release. Both CRH and UCNI antibodies significantly decreased mRNA and protein expression of synthetic enzymes cytosolic phospholipase A₂ (cPLA₂) and cyclooxygenase (COX)-2 and increased mRNA and protein expression of 15-hydroxyprostaglandin dehydrogenase (PGDH), the key enzyme of PG metabolism. CRH-R1/-R2 antagonist astressin and CRH-R1 antagonist antalarmin significantly inhibited PGE₂ release, whereas CRH-R2 antagonist astressin-2b had no effect on PGE₂ release. Administration of astressin decreased expression of cPLA₂ but had no effect on COX-2 expression. Antalarmin reduced cPLA₂ and COX-2 expression, whereas astressin-2b did not alter cPLA₂ expression but increased COX-2 expression. PGDH expression was enhanced by these three antagonists. Cells treated with exogenous CRH and UCNI showed an increase in PGE₂ release and expression of cPLA₂ and COX-2 but a decrease in PGDH expression. UCNII and UCNIII had no effect on PGE₂ release but decreased COX-2 and PGDH expression. Our results suggested CRH and CRH-related peptides act on CRH-R1 and CRH-R2 to exert different effects on PG biosynthetic enzymes cPLA₂ and COX-2 and thereby modulate output of PGs from placenta, which would be important for controlling pregnancy and parturition.